These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22229697)

  • 1. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
    Balagué C; Pont M; Prats N; Godessart N
    Br J Pharmacol; 2012 Jun; 166(4):1320-32. PubMed ID: 22229697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
    Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
    Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aclidinium bromide, tofacitinib citrate, and teriflunomide.
    Hussar DA; Hurrey NJ
    J Am Pharm Assoc (2003); 2013; 53(1):106-10. PubMed ID: 23636164
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
    Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
    Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo
    Raychaudhuri S; Abria C; Harmany ZT; Smith CM; Kundu-Raychaudhuri S; Raychaudhuri SP; Chaudhari AJ
    Int J Rheum Dis; 2019 Dec; 22(12):2165-2169. PubMed ID: 31659868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
    LaBranche TP; Jesson MI; Radi ZA; Storer CE; Guzova JA; Bonar SL; Thompson JM; Happa FA; Stewart ZS; Zhan Y; Bollinger CS; Bansal PN; Wellen JW; Wilkie DP; Bailey SA; Symanowicz PT; Hegen M; Head RD; Kishore N; Mbalaviele G; Meyer DM
    Arthritis Rheum; 2012 Nov; 64(11):3531-42. PubMed ID: 22899318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
    Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D
    Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Delivery of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the Treatment of Rheumatoid Arthritis: In Vitro Characterization, Pharmacodynamic and Biochemical Investigations.
    Pandey S; Kumar V; Leekha A; Rai N; Ahmad FJ; Verma AK; Talegaonkar S
    Pharm Res; 2018 Sep; 35(11):201. PubMed ID: 30187188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronate-functionalized hydroxyapatite nanoparticles laden with methotrexate and teriflunomide for the treatment of rheumatoid arthritis.
    Pandey S; Rai N; Mahtab A; Mittal D; Ahmad FJ; Sandal N; Neupane YR; Verma AK; Talegaonkar S
    Int J Biol Macromol; 2021 Feb; 171():502-513. PubMed ID: 33422513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.
    Riese RJ; Krishnaswami S; Kremer J
    Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):513-26. PubMed ID: 20732649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [JAK inhibitor].
    Yamaoka K; Tanaka Y
    Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
    Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
    Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib: A Review in Rheumatoid Arthritis.
    Dhillon S
    Drugs; 2017 Dec; 77(18):1987-2001. PubMed ID: 29139090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K; Tanaka Y
    Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
    Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
    Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.